What is Dentsply Sirona Inc. (XRAY) DCF Fair Value and Intrinsic Value in 2026?

Dentsply Sirona Inc. (XRAY) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Dentsply Sirona Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

Dentsply Sirona Inc. operates in the Healthcare sector (Medical Instruments & Supplies) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Dentsply Sirona Inc.'s financial health rating and Piotroski F-Score?

Dentsply Sirona Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Dentsply Sirona Inc. (XRAY) for quarterly SEC filing thesis breaks?

LocalAlpha audits Dentsply Sirona Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksXRAY

XRAY

DENTSPLY SIRONA Inc.Healthcare / Medical Instruments & SuppliesINTACT

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Share Price

$10.39

52W: $9.41 - $14.76

DCF Fair Value

$3.06

-239.5% Premium

Thesis Hub

P/E (TTM)

20x

ROIC

Operating Margin

9.2%

FCF Yield

6.9%

Debt / Equity

1.72x

Piotroski Score

6/9

Altman Z-Score

2.27

Market Cap

$2.1B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($3.06)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$3.06

MOS Buy Target (-25%)

$2.30

Valuation Overlays: DCF Fair Value ($3.06) 25% MOS Buy Target ($2.30)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$10.39

DCF Fair Value

$2.99

-247.9% Premium

Starting Free Cash Flow ($M)$142M

$100M$142M (Reported)$50,000M

Stage 1 Growth (Years 1-5)5.3%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$2,100M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$1.2B

PV of Terminal Value

$1.5B

Implied Enterprise Value

$2.7B

Implied Equity Value

$0.6B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$150	$157	$166	$175	$184	$192	$201	$210	$219	$229
Present Value (PV)	$137	$133	$128	$124	$119	$115	$110	$105	$101	$97

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number

N/A

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

Not calculable here: the formula takes a square root of EPS × book value, so it breaks down when trailing earnings (or book value) are negative. A company losing money has no defensive-investor price under Graham's classic test — lean on the DCF and solvency scores instead.

EPS: $-2.73BVPS: $6.58

Revised Graham Formula

N/A

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings6.5% Yield

$0.68 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.1BYield: 6.5%

Reverse DCF: Market Growth Expectation

EXTREMELY LOW BARRIER

1.4% CAGR (Next 10 Yrs)

At the current price of $10.39, the market is assuming the business will compound Free Cash Flow at 1.4% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil XRAY with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for DENTSPLY SIRONA Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 9.2% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track XRAY & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: DENTSPLY SIRONA Inc. (XRAY) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for DENTSPLY SIRONA Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, DENTSPLY SIRONA Inc. has an estimated DCF intrinsic fair value of $3.06 per share compared to its current market price of $10.39. This represents an estimated 239.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $N/A.